RESEARCH USE ONLY
This protocol template is a reference scaffold for laboratory, in-vitro, and animal-model research planning. It is not medical advice and is not intended for human administration. All ORYN peptides are sold strictly for research use.
CJC-1295 + Ipamorelin Pen GH-Axis Research Stack
CJC-1295 and ipamorelin are the most commonly paired peptides in GH-axis research. CJC-1295 is a GHRH analogue that drives GHRH receptor activation, while ipamorelin is a GHRP that activates the separate ghrelin/GHS-R receptor pathway. The two together produce a combined pulse that is larger than either alone — a pattern extensively documented in the pulsatility research literature. This protocol template scaffolds a 12-week research block using both ORYN pens in parallel.
DURATION
12-week research block
FREQUENCY
Twice-daily split administration (morning and pre-sleep)
PEPTIDES
CJC-1295 + Ipamorelin
CATEGORY
GH-axis research stack
Pens used in this protocol
Scientific background
The CJC-1295 + ipamorelin combination is based on the observation that GH release is driven by two independent receptor pathways: GHRH receptors (driven by CJC-1295) and GHS receptors (driven by ipamorelin). Stimulating both simultaneously produces a larger and cleaner GH pulse than either pathway alone, which is why the combination has become the standard research stack for GH-axis pulsatility studies. The pen format matters for this protocol because the twice-daily split timing (morning and pre-sleep) needs reproducible administered amounts across 12 weeks — any drift in one of the two peptides would confound the combined-pulse endpoint data.
RESEARCH FOCUS
Growth hormone releasing hormone (GHRH) + growth hormone releasing peptide (GHRP) synergy and GH-axis pulsatility research
Protocol overview
The standard GH-axis research block runs 12 weeks with both peptides administered twice daily (morning and pre-sleep). The pre-sleep administration aligns with the natural GH pulse pattern observed in mammalian research. Both pens run in parallel on the same schedule — the researcher administers one, then the other, within a few minutes. The 12-week block is long enough to observe downstream GH-axis endpoints (IGF-1 levels, body-composition shifts in animal models) but short enough to remain a single research cycle.
Protocol phases
PHASE 1
Baseline week
DURATION
Days -7 to 0
DIAL SETTING
No administration
Baseline endpoint measurements before protocol start. IGF-1 baseline, body-composition baseline, and any study-specific GH-axis endpoints.
PHASE 2
Research block
DURATION
Weeks 1-12
DIAL SETTING
Twice-daily for both peptides (morning + pre-sleep)
12 weeks of parallel twice-daily administration. Both pens are administered at the same two time points each day. The pre-sleep timing aligns with the natural nocturnal GH pulse that both peptides are investigated against. Click-count accuracy matters especially here — two separate pens, two administrations per day, 84 total days = 168 separate administered events per pen across the full block.
PHASE 3
Washout & assessment
DURATION
Weeks 13-14
DIAL SETTING
No administration
2-week washout before post-protocol endpoint measurements. IGF-1 clears within a week after cessation, so the 2-week window captures both peak post-protocol response and early clearance.
Key considerations
- •Research-use only. This protocol is for laboratory, in-vitro, and animal-model research planning — not human administration.
- •Both peptides have relatively short half-lives in most animal models, which is why the twice-daily split is used — it maintains more stable exposure across the 24-hour cycle.
- •Timing matters for the pre-sleep administration — the natural GH pulse occurs during the first few hours of sleep in mammalian research models, so alignment of the pre-sleep dose is a repeatability variable worth logging.
- •Both pens should come from the same batch where possible. Document the batch IDs for both pens at the start of the research block.
- •Avoid administering on an immediately post-feeding timeline — ghrelin-pathway peptides like ipamorelin are affected by meal timing in the research literature.
Why the pen format for this protocol
- →Two pens running in parallel is trivial with the dial-a-dose format — one administration after the other, no reconstitution between pens.
- →Twice-daily × 12 weeks = 168 administrations per pen. The <2% click variance is the core reproducibility property that makes this protocol replicable.
- →Pre-mixed format removes the main source of variance between the two peptides (reconstitution-dilution error), which matters when the combined pulse is the endpoint.
- →Refrigerated stability across the full 12-week block means both pens remain batch-locked for the duration.
- →The pen log makes research-notebook logging simple: record dial setting + click count + time for each administration, twice per day.
Literature references
The GH-axis pulsatility research literature around CJC-1295 + ipamorelin is extensive. Key references include work on combined GHRH/GHRP synergy (Bowers et al.), ipamorelin specificity (Raun et al.), and CJC-1295 pharmacokinetics (Ionescu et al.). Research protocols typically reference one of these literature streams depending on the specific endpoint — pulsatility, IGF-1 downstream response, or body-composition research.
STACKING OPTIONS
This protocol is itself a stacking protocol — CJC-1295 + ipamorelin is the canonical GH-axis stack. Some longer research designs add BPC-157 for tissue-repair endpoints on the same timeline, or tesamorelin as a CJC-1295 alternative in lipolytic research designs. ORYN ships both CJC-1295 and ipamorelin as independent pens with their own CoAs, so the stack is run in parallel rather than as a pre-formulated blend.
Common research endpoints
◆
GH pulsatility endpoints — pulse amplitude, pulse frequency, 24-hour GH profiles
◆
IGF-1 downstream endpoints — serum IGF-1 levels at weeks 4, 8, and 12
◆
Body-composition endpoints in animal models
◆
Sleep-timing endpoints — pre-sleep administration alignment with the natural GH pulse
◆
Tolerability endpoints — administration-site observations, appetite patterns
FAQ
Why stack CJC-1295 and ipamorelin instead of using one?
GH release is driven by two independent receptor pathways (GHRH and GHS receptors). Stimulating both simultaneously produces a larger and cleaner GH pulse than either alone — this is the pulsatility-research rationale that drives the stacking approach in the published literature.
Why twice-daily instead of once-daily?
Both peptides have short half-lives in most animal models. Twice-daily administration (morning + pre-sleep) maintains more stable exposure and aligns the pre-sleep dose with the natural nocturnal GH pulse that is the primary research endpoint.
Is the CJC-1295 DAC or non-DAC variant used here?
ORYN ships the CJC-1295 pen with clearly labelled variant information on the CoA. Non-DAC variants have shorter half-lives and are typically used with twice-daily protocols like this one. DAC variants have extended half-lives and use different protocol structures. Check the batch CoA before protocol design.
Can ipamorelin be used alone?
Yes — ipamorelin monotherapy protocols exist in the research literature. The GH pulse is smaller than the stacked version, but the research endpoint is still measurable. The stack is preferred when the research question specifically investigates combined GHRH/GHS synergy.
What's the pre-sleep window?
The natural GH pulse occurs in the first few hours of sleep in most mammalian research models. Administration 30-60 minutes before the subject's sleep window is the typical alignment point. This is a timing-repeatability variable that should be documented consistently across the 12-week block.
Order the pens for this research protocol
Every ORYN peptide pen ships with a Certificate of Analysis, full batch documentation, and the pen-format mechanical accuracy that makes protocol replicability possible. Research use only.
OTHER RESEARCH PROTOCOLS
RECOVERY & TISSUE REPAIR
BPC-157 recovery
28-day research block · Daily administration, typically split across two time points
METABOLIC & INCRETIN RESEARCH
Tirzepatide metabolic
12-week research block · Weekly single administration
LONGEVITY & MITOCHONDRIAL RESEARCH
NAD+ longevity
8-week loading + maintenance block · Daily during loading, alternate-day during maintenance
SKIN & COLLAGEN RESEARCH
GHK-Cu skin
6-week research block · Daily single administration